SCHEMBL7264668

SCHEMBL7264668

CCC(CC(=O)O)(NC(=O)OC(C)(C)C)c1ccc(N)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
EPHX2 P34913 1/20 0.35
KDM4E B2RXH2 1/20 0.34
SLC22A6 Q4U2R8 1/20 0.34
SLC22A8 Q8TCC7 1/20 0.34
CA12 O43570 5/20 0.33
CA1 P00915 5/20 0.33
CA7 P43166 1/20 0.33
CA14 Q9ULX7 1/20 0.33
ESRRG P62508 1/20 0.33
CA2 P00918 4/20 0.33
CA9 Q16790 4/20 0.33
PTPRB P23467 1/20 0.33
IDO1 P14902 1/20 0.33
AKT1 P31749 2/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1274265 0.88 CYP2C19 (0.50) HIF1ACYP2C19NPC1RAB9ACA12
SCHEMBL6513375 0.82 HIF1A (0.39) HIF1ACYP2C19MAPTEPHX2KDM4E
SCHEMBL1141266 0.76 NPC1 (0.47) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL10282363 0.75 EPHX2 (0.39) MAPTNPC1RAB9AEPHX2KDM4E
SCHEMBL5505022 0.73 EPHX2 (0.37) MAPTNPC1RAB9AEPHX2KDM4E
SCHEMBL7233451 0.72 PTPRB (0.45) MAPTNPC1RAB9AEPHX2KDM4E
SCHEMBL18054013 0.72 EPHX2 (0.38) CYP2C19MAPTNPC1RAB9AEPHX2
SCHEMBL2982545 0.72 PTPRB (0.40) EPHX2CA12CA1CA7CA14
SCHEMBL2992285 0.72 PTPRB (0.40) EPHX2CA12CA1CA7CA14
SCHEMBL398349 0.72 EPHX2 (0.42) MAPTNPC1RAB9AEPHX2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6545013-B2 Of squaric acids; inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells. CELLTECH R&D LIMITED (GB) 2003-04-08 US disclosed
EP-1286995-A1 2,7-NAPHTHYRIDINE DERIVATIVES Celltech R&D Limited (GB) 2003-03-05 EP disclosed
US-20020115684-A1 2, 7-naphthyridine derivatives CELLTECH R&D, LTD. (GB) 2002-08-22 US disclosed
WO-2001092256-A1 2,7-NAPHTHYRIDINE DERIVATIVES CELLTECH R & D LIMITED (GB) 2001-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115684-A1 2, 7-naphthyridine derivatives VCAM1, ICAM1, SELL HIF1A 571/4885CYP2C19 3889/4885MAPT 4573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.